[Code of Federal Regulations] [Title 21, Volume 4] [Revised as of April 1, 2006] From the U.S. Government Printing Office via GPO Access [CITE: 21CFR207.3] [Page 118-119] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) PART 207_REGISTRATION OF PRODUCERS OF DRUGS AND LISTING OF DRUGS IN COMMERCIAL DISTRIBUTION--Table of Contents Subpart A_General Sec. 207.3 Definitions. Subpart A_General Sec. 207.3 Definitions. 207.7 Establishment registration and product listing for human blood and blood products and for medical devices. Subpart B_Exemptions 207.10 Exemptions for establishments. Subpart C_Procedures for Domestic Drug Establishments 207.20 Who must register and submit a drug list. 207.21 Times for registration and drug listing. 207.22 How and where to register and list drugs. 207.25 Information required in registration and drug listing. 207.26 Amendments to registration. 207.30 Updating drug listing information. 207.31 Additional drug listing information. 207.35 Notification of registrant; drug establishment registration number and drug listing number. 207.37 Inspection of registrations and drug listings. 207.39 Misbranding by reference to registration or to registration number. Subpart D_Procedure for Foreign Drug Establishments 207.40 Establishment registration and drug listing requirements for foreign establishments. Authority: 21 U.S.C. 321, 331, 351, 352, 355, 360, 360b, 371, 374, 381, 393; 42 U.S.C. 262, 264, 271. Source: 45 FR 38043, June 6, 1980, unless otherwise noted. (a) The following definitions apply to this part: (1) Act means the Federal Food, Drug, and Cosmetic Act approved June 25, 1938 (52 Stat. 1040 et seq., as amended (21 U.S.C. 301-392)), except as otherwise provided. (2) Advertising and labeling include the promotional material described in Sec. 202.1(l) (1) and (2) respectively. (3) Any material change includes but is not limited to any change in the name of the drug, any change in the identity or quantity of the active ingredient(s), any change in the identity or quantity of the inactive ingredient(s) where quantitative listing of all ingredients is required by Sec. 207.31(a)(2), any significant change in the labeling of a prescription drug, and any significant change in the label or package insert of an over-the-counter drug. Changes that are not significant include changes in arrangement or printing or changes of an editorial nature. (4) Bulk drug substance means any substance that is represented for use in a drug and that, when used in the manufacturing, processing, or packaging of [[Page 119]] a drug, becomes an active ingredient or a finished dosage form of the drug, but the term does not include intermediates used in the synthesis of such substances. (5) Commercial distribution means any distribution of a human drug except for investigational use under part 312 of this chapter, and any distribution of an animal drug or animal feed bearing or containing an animal drug for noninvestigational uses, but the term does not include internal or interplant transfer of a bulk drug substance between registered establishments within the same parent, subsidiary, and/or affiliate company. For foreign establishments, the term ``commercial distribution'' shall have the same meaning except that the term shall not include distribution of any drug that is neither imported nor offered for import into the United States. (6) Drug product salvaging means the act of segregating drug products that may have been subjected to improper storage conditions, such as extremes in temperature, humidity, smoke, fumes, pressure, age, or radiation, for the purpose of returning some or all of the products to the marketplace. (7) Establishment means a place of business under one management at one general physical location. The term includes, among others, independent laboratories that engage in control activities for a registered drug establishment (e.g., consulting laboratories), manufacturers of medicated feeds and of vitamin products that are drugs in accordance with section 201(g) of the act, human blood donor centers, and animal facilities used for the production or control testing of licensed biologicals, and establishments engaged in drug product salvaging. (8) Manufacturing or processing means the manufacture, preparation, propagation, compounding, or processing of a drug or drugs as used in section 510 of the act and is the making by chemical, physical, biological, or other procedures of any articles that meet the definition of drugs in section 201(g) of the act. The term includes manipulation, sampling, testing, or control procedures applied to the final product or to any part of the process. The term also includes repackaging or otherwise changing the container, wrapper, or labeling of any drug package to further the distribution of the drug from the original place of manufacture to the person who makes final delivery or sale to the ultimate consumer. (9) Representative sampling of advertisements means typical advertising material (excluding labeling as determined in Sec. 202.1(l) (1) and (2)) that gives a balanced picture of the promotional claims used for the drug, e.g., if more than one medical journal advertisement is used but the promotional content is essentially identical, only one need be submitted. (10) Representative sampling of any other labeling means typical labeling material (excluding labels and package inserts) that gives a balanced picture of the promotional claims used for the drug, e.g., if more than one brochure is used but the promotional content is essentially identical, only one need be submitted. (11) United States agent means a person residing or maintaining a place of business in the United States whom a foreign establishment designates as its agent. This definition excludes mailboxes, answering machines or services, or other places where an individual acting as the foreign establishment's agent is not physically present. (b) The definitions and interpretations of terms in sections 201, 502(e), and 510 of the act apply to the use of terms in this part. [45 FR 38043, June 6, 1980, as amended at 55 FR 11576, Mar. 29, 1990; 66 FR 59156, Nov. 27, 2001]